Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

Downloaded from https://aidsinfo.nih.gov/guidelines on 3/17/2020

Visit the AIDSinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
**Atazanavir (Reyataz, ATV)**
*(Last updated December 24, 2019; last reviewed December 24, 2019)*

**Animal Studies**

**Carcinogenicity**

In *in vitro* and *in vivo* assays, atazanavir (ATV) shows evidence of clastogenicity but not mutagenicity. Two-year carcinogenicity studies in mice and rats were conducted with ATV. In female mice, the incidence of benign hepatocellular adenomas increased at systemic exposures that were 2.8-fold to 2.9-fold higher than those seen in humans who received the recommended therapeutic dose (ATV 300 mg boosted with ritonavir [RTV] 100 mg once daily). There was no increase in the incidence of tumors in male mice at any dose and no significant increase in the incidence of neoplasms in rats at systemic exposures up to 1.1-fold (in males) or 3.9-fold (in females) higher than those seen in humans who received the recommended therapeutic dose.1

**Reproduction/Fertility**

No effect of ATV on reproduction or fertility in male and female rodents was observed at drug exposure levels (as measured by area under the curve [AUC]) that were 0.9-fold (in males) and 2.3-fold (in females) higher than the exposures achieved in humans who received the recommended therapeutic dose.1

**Teratogenicity/Adverse Pregnancy Outcomes**

In animal reproduction studies, there was no evidence of teratogenicity in offspring born to animals that had systemic ATV exposure levels (as measured by AUC) that were 0.7 times (in rabbits) and 1.2 times (in rats) those observed in humans who received the recommended therapeutic dose. In developmental toxicity studies in rats, maternal dosing (through pregnancy and lactation) that produced systemic ATV exposure that was 1.3 times the human exposure resulted in reversible neonatal growth retardation. However, offspring were unaffected at lower maternal doses that produced systemic drug exposures equivalent to those observed in humans who received the recommended therapeutic dose.1 A separate study demonstrated an association between maternal protease inhibitor (PI) use (including the use of ATV) and lower progesterone levels, which correlated with lower birthweight in mice.2,3

**Placental and Breast Milk Passage**

ATV maternal-to-fetal (transplacental) transfer is reduced, which may be because ATV is a substrate of the placental drug efflux ATP-binding cassette transporter p-glycoprotein.4

ATV is excreted in the milk of lactating rats. Maternal ATV use in rats that produced systemic ATV exposure that was 1.3 times the human exposure was associated with neonatal growth restriction that reversed after weaning.1

**Human Studies in Pregnancy**

**Pharmacokinetics**

Several studies have investigated the pharmacokinetics (PKs) and virologic outcomes of using atazanavir/ritonavir (ATV/r) during pregnancy.5 Overall, most pregnant women achieved undetectable HIV RNA at the time of delivery in these studies.1,6-10 In a retrospective study that measured trough ATV concentrations at a median of 30 weeks gestation in 19 pregnant women (including 14 who were in the third trimester of pregnancy) who received ATV 300 mg and RTV 100 mg once daily, all but two women had trough ATV concentrations >100 ng/mL.11

In studies that evaluated full PK profiles of daily ATV 300 mg with RTV 100 mg during pregnancy, ATV AUC was lower during pregnancy than the ATV AUC reported in other studies of nonpregnant adults with HIV.6,8,9,12,13 In one of the studies, there was no difference between ATV AUC during pregnancy and postpartum, but AUC at both times was lower than the AUC observed in nonpregnant historic controls with HIV.8 In the other studies, ATV AUC was lower during pregnancy than it was in the same patients postpartum.
Intracellular ATV levels in women taking ATV 300 mg and RTV 100 mg appear to be stable throughout pregnancy. Genetic variants appear to partially explain the interpatient variability in third trimester ATV exposure seen in pregnant women who receive ATV/r.13 ATV/r combined with tenofovir disoproxil fumarate (TDF) and emtricitabine provides a complete, once-daily antiretroviral therapy regimen for pregnant women. However, the ATV AUC of pregnant women in the third trimester who received concomitant TDF was 30% lower than the ATV AUC of women who were not receiving concomitant TDF, an effect similar to that seen in nonpregnant adults. The increase in ATV AUC postpartum relative to ATV AUC in the third trimester was similar for women taking concomitant TDF and for those not taking concomitant TDF.9 On the other hand, a smaller PK study demonstrated that concomitant TDF did not result in lower ATV AUC or a higher risk of ATV trough concentrations <0.15 mg/L (the target trough concentration for treatment-naive patients) in pregnant women during their third trimester.16 In a therapeutic drug monitoring (TDM) study of 103 women (who were mostly African) in Paris, the proportions of women with ATV trough concentration <0.15 mg/L were similar for women who did and women who did not take concomitant TDF.10

In studies that evaluated the use of once-daily ATV 400 mg with RTV 100 mg during pregnancy, pregnant women who received this increased dose without TDF had an ATV AUC that was equivalent to the ATV AUC seen in historic nonpregnant controls with HIV who received the standard ATV 300 mg dose without TDF. Pregnant women who received the increased ATV 400 mg dose with TDF had an ATV AUC equivalent to that seen in nonpregnant patients with HIV who received standard ATV 300 mg dose with TDF.6,7 Although some experts recommend an increased dose of ATV for all women during the second and third trimesters, the package insert recommends the use of an increased dose of ATV during the second and third trimesters only for treatment-experienced pregnant women who are also receiving either TDF or an H2-receptor antagonist. TDM of ATV in pregnancy may also be useful.17 For additional details about interactions between concomitant medications, please see Drug-Drug Interactions in the Adult and Adolescent Antiretroviral Guidelines.

The pharmaco-enhancing effect of cobicistat (COBI) on ATV is impacted during pregnancy. Pregnant women who received ATV boosted with COBI had trough ATV concentrations that were 80% and 85% lower during the second and third trimesters than historical ATV trough concentrations in nonpregnant adults with HIV. Concomitant use of ATV and COBI is not recommended during pregnancy because of these substantial reductions in drug exposures (see Cobicistat).19

Placental and Breast Milk Passage

In studies of women receiving ATV/r combination therapy during pregnancy, cord blood ATV concentration averaged 13% to 21% of maternal serum levels at delivery.1,8,9 In a study of three women, the median ratio of breast milk ATV concentration to plasma ATV concentration was 0.13.20

Teratogenicity/Adverse Pregnancy Outcomes

In a multicenter study that evaluated a U.S. cohort of children who were exposed to HIV but who did not contract HIV, first-trimester ATV exposure was associated with increased odds of congenital anomalies of the skin (adjusted odds ratio [aOR] 5.24; P = 0.02) and the musculoskeletal system (aOR 2.55; P = 0.007).21 On the other hand, there was no association between first-trimester ATV exposure and birth defects in a French cohort, although this study had <50% power to detect an aOR of 1.5.22 The Antiretroviral Pregnancy Registry has monitored sufficient numbers of first-trimester exposures to ATV in humans to be able to detect at least a 1.5-fold increase in the risk of overall birth defects, and no such increase in birth defects has been observed with ATV. The prevalence of birth defects with first-trimester ATV exposure was 2.2% (29 of 1,328 births; 95% CI, 1.5% to 3.1%) compared with a 2.7% total prevalence in the U.S. population, based on Centers for Disease Control and Prevention surveillance.23
Other Safety Data

Elevation in indirect (unconjugated) bilirubin that can be attributed to ATV-related inhibition of hepatic uridine diphosphate glucuronosyltransferase (UGT) enzyme occurs frequently during treatment with ATV, including during pregnancy. It is unknown whether elevated maternal indirect bilirubin throughout pregnancy has any effects on the fetus. Dangerous or pathologic postnatal elevations in bilirubin have not been reported in infants born to mothers who received ATV during pregnancy. In some studies, neonatal bilirubin elevations that require treatment with phototherapy occur more frequently after prenatal ATV exposure. However, decisions to use phototherapy frequently are subjective and guidelines for phototherapy vary across countries, making it difficult to compare the severity of hyperbilirubinemia between patients within a study and across different studies. Elevated neonatal bilirubin in neonates exposed to ATV is not associated with UGT-1 genotypes that have been linked decreased UGT function.

Hypoglycemia (glucose <40 mg/dL) that could not be attributed to maternal glucose intolerance, difficult delivery, or sepsis was reported in three of 38 ATV-exposed infants who had glucose samples collected during the first day of life. All three hypoglycemic infants’ glucose samples were adequately collected and processed in a timely fashion. This report of infant hypoglycemia is similar to a prior report in which two of 14 infants who were exposed to PIs (nelfinavir, saquinavir, and indinavir) developed hypoglycemia during the first day of life; both infants with hypoglycemia had been exposed to nelfinavir.
Excerpt from Table 8

**Note:** When using FDC tablets, refer to other sections in Appendix B and Table 8 for information about the dosing and safety of individual drug components of the FDC tablet during pregnancy.

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation) Trade Name</th>
<th>Formulation</th>
<th>Dosing Recommendations$^a$</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
</table>
| Atazanavir (ATV) Reyataz              | ATV (Reyataz) Capsules: • 100 mg (generic product only) • 150 mg$^d$ • 200 mg$^d$ • 300 mg$^d$ Oral Powder: • 50 mg packet | Standard Adult Doses In ARV-Naive Patients without RTV Boosting: • ATV 400 mg once daily with food; ATV without RTV boosting is not recommended when used with TDF, H2-receptor antagonists, PPIs, or during pregnancy.
In ARV-Naive Patients with RTV Boosting: • ATV 300 mg plus RTV 100 mg once daily with food
• When combined with EFV in ARV-naive patients: ATV 400 mg plus RTV 100 mg once daily with food
In ARV-Experienced Patients:
• ATV 300 mg plus RTV 100 mg once daily with food
• **Do not use** with PPIs or EFV
In ARV-Experienced Patients Who Are Receiving an H2-Receptor Antagonist:
• ATV 300 mg plus RTV 100 mg once daily with food

In ARV-Experienced Patients Who Are Receiving an H2-Receptor Antagonist and TDF:
• ATV 400 mg plus RTV 100 mg once daily with food
| Powder Formulation:
• Oral powder is taken with RTV once daily with food at the same recommended adult dose as the capsules.
| ATV/c (Evotaz):
• One tablet once daily with food | Low placental transfer to fetus.$^b$
No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects).
Must be given with RTV boosting in pregnancy.
Effect of in utero ATV exposure on infant indirect bilirubin levels is unclear. Nonpathologic elevations of neonatal bilirubin have been observed in some, but not all, clinical trials to date.
Oral powder (but not capsules) contains phenylalanine, which can be harmful to patients with phenylketonuria.

Use of ATV/c is **not recommended** during pregnancy. See Recommendations for Use of Antiretroviral Drugs During Pregnancy, Table 4, and Table 5 for discussions about avoiding the use of ATV/c during pregnancy.

---

$^a$Recommended dosing and safety data are based on clinical trials, with the exception of ATV/c (Evotaz). Data from nonclinical studies are not available.

$^b$Use of ATV/c is **not recommended** during pregnancy. See Recommendations for Use of Antiretroviral Drugs During Pregnancy, Table 4, and Table 5 for discussions about avoiding the use of ATV/c during pregnancy.

---

Recommended dosing and safety data are based on clinical trials, with the exception of ATV/c (Evotaz). Data from nonclinical studies are not available.

---

**ATV (Reyataz)**

**ATV/c (Evotaz)**
Excerpt from Table 8

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendationsa</th>
<th>Use in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ATV (Reyataz):</strong></td>
<td></td>
<td>Use of unboosted ATV <strong>is not recommended</strong> during pregnancy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Use of ATV <strong>is not recommended</strong> for ARV-experienced pregnant women who are taking TDF and an H2-receptor antagonist.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Use of an increased dose (ATV 400 mg plus RTV 100 mg once daily with food) during the second and third trimesters results in plasma ATV concentrations equivalent to those seen in nonpregnant adults receiving standard dosing. Although some experts recommend increased ATV dosing in all women during the second and third trimesters, the package insert recommends increased ATV dosing only for ARV-experienced pregnant women in the second and third trimesters who are also receiving either TDF or an H2-receptor antagonist.</td>
<td></td>
</tr>
<tr>
<td><strong>ATV+c (Evotaz):</strong></td>
<td></td>
<td>Insufficient data to make dosing recommendation in pregnancy (see COBI).</td>
<td></td>
</tr>
</tbody>
</table>

For guidance about the use of combination products in pregnancy, please see the specific sections on other components (i.e., COBI).

---

**References**


---

*Individual ARV drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Antiretroviral Guidelines, Appendix B, Table 10).*

*Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio:*

- **High:** >0.6
- **Moderate:** 0.3–0.6
- **Low:** <0.3

*Generic formulation available*

**Key:** ARV = antiretroviral; ATV = atazanavir; ATV/c = atazanavir/cobicistat; COBI = cobicistat; EFV = efavirenz; FDC = fixed-dose combination; PK = pharmacokinetic; PPI = proton pump inhibitor; RTV = ritonavir; TDF = tenofovir disoproxil fumarate


Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

G-73

Downloaded from https://aidsinfo.nih.gov/guidelines on 3/17/2020
